Comment & Analysis

AstraZeneca'’s efforts to turn Brilinta into a blockbuster franchise show the group to be nothing ...

Even without a sham control group, the Anthem-HF trial of Cyberonics’ vagus nerve stimulation (VNS) ...

Ordinarily, a Japanese regulatory ruling on a new drug’s price would merit little more than a ...

MedTech

EventAnalyzer

Latest
 

Therapeutic Focus

Market Moving Events

EP Vantage Interviews